Acute Effects of Post-Exercise Hyperoxia on Recovery in Cycling
This study examines whether exposition to hyperbaric oxygen after a road-race simulation can help competitive cyclists recover and perform better the following day.
Hyperbaric oxygen, which involves breathing oxygen inside a pressurized chamber, is used as a recovery method in elite and professional sport. Its effectiveness, however, remains controversial: despite this widespread use, there is a lack of solid scientific evidence that a single HBO session after strenuous endurance exercise actually improves recovery, or that clarifies how the amount of oxygen exposure influences any benefit.
The study includes healthy male road cyclists between 18 and 40 years of age who compete at the national level in Belgium. After completing a fatiguing cycling session, each participant is randomly assigned to one of four groups receiving different levels of oxygen exposure during recovery.
Two groups breathe oxygen under increased pressure inside a chamber at either 2.5 or 1.4 atmospheres absolute. A third group breathes oxygen at normal pressure. The fourth group receives a sham condition that reproduces the treatment setting without active oxygen exposure.
The study is double-blind, meaning that neither the participants nor the researchers assessing the outcomes know which condition each participant receives.
The main goal is to determine whether a single session of post-exercise HBO improves next-day endurance performance, and whether higher oxygen exposure produces greater effects.
The researchers also collect blood samples and physiological measurements to better understand how the body recovers.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Théo A MAHY, MSc
- Numéro de téléphone: +32 10 474 489
- E-mail: theo.mahy@uclouvain.be
Lieux d'étude
-
-
Brabant-Wallon
-
Louvain-la-Neuve, Brabant-Wallon, Belgique, 1348
- Recrutement
- Institute of Neuroscience, Université catholique de Louvain
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Road cyclists competing in Elite 2 (Elite without professional contract) or Under-23 (U23) categories or equivalent [Participation in national-level Belgian competitions within the previous 12 months. No specific ranking, finishing position, or performance threshold is required.]
- ≥ 2 consecutive years of cycling experience at regional or national level, with structured and periodized training
- Cycling-specific training volume ≥ 8 h a week over the preceding 10 weeks
- Stable training load in the weeks preceding inclusion, with no major changes due to injury, illness, or abnormal overload
- Measured VO₂max ≥ 60 ml/kg/min
Exclusion Criteria:
- Presence of significant cardiovascular, pulmonary, neurological, ENT, or metabolic disease, including but not limited to: Uncontrolled arterial hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 110 mmHg) ; Unstable heart disease or decompensated cardiomyopathy
- Contraindications to hyperbaric exposure, including: Untreated pneumothorax, History of spontaneous pneumothorax without medical clearance ; Pulmonary conditions associated with air trapping (e.g. emphysema or bullous lung disease), or abnormal thoracic imaging when indicated ; Recent thoracic surgery
- Neurological contraindications, including epilepsy, history of oxygen-induced seizures, or recent seizure activity, and any association with cannabis use
- Ear, sinus, or Eustachian tube disorders preventing adequate pressure equalization, including active infection or history of severe barotrauma
- Severe claustrophobia incompatible with chamber exposure
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: HBO 2.5 ATA
PiO₂ = 2.5 (100 % O₂ x 2.5 ATA)
|
1h intervention after a fatiguing exercise
|
|
Expérimental: HBO 1.4 ATA
PiO₂ = 1.4 (100 % O₂ x 1.4 ATA)
|
1h intervention after a fatiguing exercise
|
|
Expérimental: NBO 1.0 ATA
PiO₂ = 1.0 (100 % O₂ x 1.0 ATA)
|
1h intervention after a fatiguing exercise
|
|
Comparateur factice: SHAM
PiO₂ = 0.21 (21 % O₂ x 1.0 ATA)
|
1h intervention after a fatiguing exercise
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Next-day endurance performance : Percent decrement in time to exhaustion from baseline
Délai: Throughout the entire study, approximately during 18 months
|
Endurance performance measured by a cycling time-to-exhaustion test at 105% of the lactate threshold power, expressed as the percentage decrement in time to exhaustion relative to the baseline test. Performance is compared SHAM to the other oxygen-exposure groups. |
Throughout the entire study, approximately during 18 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HBO-RISE
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .